Published in Health Qual Life Outcomes on September 05, 2013
Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary. Eur J Health Econ (2014) 0.88
Ethnic differences in health related quality of life for patients with type 2 diabetes. Health Qual Life Outcomes (2014) 0.81
Preferred Reporting Items for Studies Mapping onto Preference-Based Outcome Measures: The MAPS Statement. Pharmacoeconomics (2015) 0.80
Testing mapping algorithms of the cancer-specific EORTC QLQ-C30 onto EQ-5D in malignant mesothelioma. Health Qual Life Outcomes (2015) 0.80
Mapping FACT-P to EQ-5D in a large cross-sectional study of metastatic castration-resistant prostate cancer patients. Qual Life Res (2014) 0.79
Mapping the functional assessment of cancer therapy-breast (FACT-B) to the 5-level EuroQoL Group's 5-dimension questionnaire (EQ-5D-5L) utility index in a multi-ethnic Asian population. Health Qual Life Outcomes (2014) 0.79
Mapping and direct valuation: do they give equivalent EQ-5D-5L index scores? Health Qual Life Outcomes (2015) 0.78
Mapping Functions in Health-Related Quality of Life: Mapping from Two Cancer-Specific Health-Related Quality-of-Life Instruments to EQ-5D-3L. Med Decis Making (2015) 0.78
Level of agreement between patient-reported EQ-5D responses and EQ-5D responses mapped from the SF-12 in an injury population. Popul Health Metr (2015) 0.77
Measuring quality of life in opioid-induced constipation: mapping EQ-5D-3 L and PAC-QOL. Health Econ Rev (2016) 0.76
PREFERRED REPORTING ITEMS FOR STUDIES MAPPING ONTO PREFERENCE-BASED OUTCOME MEASURES: THE MAPS STATEMENT. Int J Technol Assess Health Care (2015) 0.75
Development of a web-based tool for the assessment of health and economic outcomes of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA). BMC Med Inform Decis Mak (2015) 0.75
Recent advances in patient and proxy-reported quality of life research. Health Qual Life Outcomes (2014) 0.75
Mapping the SRS-22r questionnaire onto the EQ-5D-5L utility score in patients with adolescent idiopathic scoliosis. PLoS One (2017) 0.75
Cost-effectiveness of adjunct non-pharmacological interventions for osteoarthritis of the knee. PLoS One (2017) 0.75
Preferred reporting items for studies mapping onto preference-based outcome measures: The MAPS statement. Health Qual Life Outcomes (2015) 0.75
Mapping of Multiple Sclerosis Walking Scale (MSWS-12) to five-dimension EuroQol (EQ-5D) health outcomes: an independent validation in a randomized control cohort. Patient Relat Outcome Meas (2016) 0.75
Preferred reporting items for studies mapping onto preference-based outcome measures: the MAPS statement. Qual Life Res (2015) 0.75
Preferred Reporting Items for Studies Mapping onto Preference-Based Outcome Measures: The MAPS Statement. Appl Health Econ Health Policy (2015) 0.75
The clinical and cost effectiveness of group art therapy for people with non-psychotic mental health disorders: a systematic review and cost-effectiveness analysis. BMC Psychiatry (2015) 0.75
Preference-based disease-specific health-related quality of life instrument for glaucoma: a mixed methods study protocol. BMJ Open (2016) 0.75
Mapping PROMIS Global Health Items to EuroQol (EQ-5D) Utility Scores Using Linear and Equipercentile Equating. Pharmacoeconomics (2017) 0.75
Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health (2012) 3.14
A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures. Eur J Health Econ (2009) 2.91
Use of quality-adjusted life years for the estimation of effectiveness of health care: A systematic literature review. Int J Technol Assess Health Care (2006) 1.91
Estimating the association between SF-12 responses and EQ-5D utility values by response mapping. Med Decis Making (2006) 1.89
Mapping FACT-P and EORTC QLQ-C30 to patient health status measured by EQ-5D in metastatic hormone-refractory prostate cancer patients. Value Health (2007) 1.78
Comparison of 5 health-related quality-of-life indexes using item response theory analysis. Med Decis Making (2009) 1.70
Cost-effectiveness of asthma control: an economic appraisal of the GOAL study. Allergy (2006) 1.62
Mapping SF-36 onto the EQ-5D index: how reliable is the relationship? Health Qual Life Outcomes (2009) 1.55
Mapping to obtain EQ-5D utility values for use in NICE health technology assessments. Value Health (2013) 1.44
Comparing the incomparable? A systematic review of competing techniques for converting descriptive measures of health status into QALY-weights. Med Decis Making (2008) 1.31
Tails from the peak district: adjusted limited dependent variable mixture models of EQ-5D questionnaire health state utility values. Value Health (2012) 1.30
Mapping the EORTC QLQ C-30 onto the EQ-5D instrument: the potential to estimate QALYs without generic preference data. Value Health (2008) 1.23
Addressing ceiling effects in health status measures: a comparison of techniques applied to measures for people with HIV disease. Health Serv Res (2008) 1.18
Predicting the EuroQol Group's EQ-5D index from CDC's "Healthy Days" in a US sample. Med Decis Making (2010) 1.16
Etanercept and efalizumab for the treatment of psoriasis: a systematic review. Health Technol Assess (2006) 1.12
Do generic utility measures capture what is important to the quality of life of people with multiple sclerosis? Health Qual Life Outcomes (2013) 1.05
Mapping the modified Rankin scale (mRS) measurement into the generic EuroQol (EQ-5D) health outcome. Med Decis Making (2009) 1.04
Mapping utility scores from the Barthel index. Eur J Health Econ (2011) 1.04
Converting the SF-12 into the EQ-5D: an empirical comparison of methodologies. Pharmacoeconomics (2009) 0.99
The relationship between EQ-5D, HAQ and pain in patients with rheumatoid arthritis. Rheumatology (Oxford) (2013) 0.97
Valuing states from multiple measures on the same visual analogue sale: a feasibility study. Health Econ (2011) 0.91
Mapping from disease-specific to generic health-related quality-of-life scales: a common factor model. Value Health (2012) 0.91
Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis. J Med Econ (2012) 0.90
Scale characteristics and mapping accuracy of the US EQ-5D, UK EQ-5D, and SF-6D in patients with rheumatoid arthritis. J Rheumatol (2010) 0.89
What value health?: A review of health state values used in early technology assessments for NICE. Appl Health Econ Health Policy (2005) 0.88
Evaluation of content on EQ-5D as compared to disease-specific utility measures. Qual Life Res (2012) 0.88
A comparison of direct and indirect methods for the estimation of health utilities from clinical outcomes. Med Decis Making (2013) 0.88
Estimating the relationship between preference-based generic utility instruments and disease-specific quality-of-life measures in severe chronic constipation: challenges in practice. Pharmacoeconomics (2011) 0.87
Which health-related quality-of-life outcome when planning randomized trials: disease-specific or generic, or both? A common factor model. Value Health (2013) 0.87
Markov blanket-based approach for learning multi-dimensional Bayesian network classifiers: an application to predict the European Quality of Life-5 Dimensions (EQ-5D) from the 39-item Parkinson's Disease Questionnaire (PDQ-39). J Biomed Inform (2012) 0.86
Mapping the EQ-5D index by UPDRS and PDQ-8 in patients with Parkinson's disease. Health Qual Life Outcomes (2013) 0.84
A comparison of physician-rated disease severity and patient reported outcomes in mild to moderately active ulcerative colitis. J Crohns Colitis (2009) 0.83
Estimating preference-based EQ-5D health state utilities or item responses from neuropathic pain scores. Patient (2012) 0.83
Constructing health state preference values from descriptive quality of life outcomes: mission impossible? Qual Life Res (1997) 0.81
Mapping analyses to estimate EQ-5D utilities and responses based on Oxford Knee Score. Qual Life Res (2012) 0.81
Mapping of the PDQ-39 to EQ-5D scores in patients with Parkinson's disease. Qual Life Res (2012) 0.80
Mapping the Oxford hip score onto the EQ-5D utility index. Qual Life Res (2012) 0.79